Thymidine Kinase: A Biomarker for Recently Diagnosed Acute Leukemia in Pediatric Patients According to the Cell Line Involved

详细信息    查看全文

• 作者：Briceida Ló ; pez-Martí ; nez^a ; Armando Vilchis Ordoñ ; ez^b ; Marcela Salazar Garcia^c ; Miguel Klü ; nder-Klü ; nder^d ; Israel Parra-Ortega^b ; Elisa Dorantes-Acosta^e ; Tania Angeles-Floriano^b ; ^{tania.angeles@yahoo.com.mx" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Acute lymphoblastic leukemia (ALL) ; Acute myeloid leukemia (AML) ; Thymidine kinase 1 (TK1) ; Deoxythymidine triphosphate (dTTP) ; Reference values (RVs)
• 刊名：Archives of Medical Research
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：46
• 期：8
• 页码：630-634
• 全文大小：274 K

文摘

Acute leukemia (AL) is a heterogeneous group of diseases characterized by a disorganized clone proliferation of hematopoietic cells. Thymidine kinase (TK) is a cell enzyme involved in DNA synthesis and is considered a cellular proliferation marker in some solid tumors.

Methods

A cross-sectional prospective and comparative study was performed in the Federico Gomez Children's Hospital in Mexico (HIMFG, in Spanish) in 125 samples of patients of the HIMFG with AL and 138 samples of children without leukemia. Serum TK levels were determined for both groups.

Results

Of the children with AL, 90 presented B-cell acute lymphoblastic leukemia (B-ALL); 13, T-cell acute lymphoblastic leukemia (T-ALL); and 22, acute myeloid leukemia (AML). A median (m) TK level of 23.7 IU (IQR 17–35.7) was observed in the group without AL and 91 IU (IQR 98–392) in the AL group. This difference was statistically significant (p <0.0001). When analyzing TK levels according to the type of leukemia, the m was as follows: 68 IU (IQR 35–118) for B-ALL, 470 IU (IQR 88–750) for AML, and 1678 IU (IQR 288–2108) for T- ALL.

Conclusion

TK is an enzyme showing heterogeneous levels in B-ALL although it is significantly increased in 90% of patients with T-ALL and AML.